venBio Select Advisor LLC lessened its position in Tricida Inc (NASDAQ:TCDA) by 1.2% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 1,750,000 shares of the company’s stock after selling 21,500 shares during the period. Tricida comprises 2.5% of venBio Select Advisor LLC’s portfolio, making the stock its 13th largest holding. venBio Select Advisor LLC owned approximately 4.16% of Tricida worth $41,265,000 at the end of the most recent quarter.
Several other large investors have also recently bought and sold shares of the company. Legal & General Group Plc acquired a new position in shares of Tricida in the third quarter valued at approximately $54,000. Great West Life Assurance Co. Can acquired a new position in shares of Tricida in the fourth quarter valued at approximately $71,000. Strs Ohio acquired a new position in shares of Tricida in the third quarter valued at approximately $100,000. TD Asset Management Inc. raised its position in shares of Tricida by 17.7% in the fourth quarter. TD Asset Management Inc. now owns 23,297 shares of the company’s stock valued at $549,000 after buying an additional 3,500 shares during the last quarter. Finally, Massachusetts Financial Services Co. MA raised its position in shares of Tricida by 2.1% in the fourth quarter. Massachusetts Financial Services Co. MA now owns 205,409 shares of the company’s stock valued at $4,844,000 after buying an additional 4,239 shares during the last quarter. 70.27% of the stock is owned by institutional investors and hedge funds.
In related news, Director Sandra I. Coufal sold 1,972 shares of the company’s stock in a transaction that occurred on Tuesday, January 29th. The shares were sold at an average price of $20.22, for a total transaction of $39,873.84. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, Director Klaus R. Dr Veitinger sold 9,814 shares of the company’s stock in a transaction that occurred on Wednesday, December 26th. The stock was sold at an average price of $24.97, for a total transaction of $245,055.58. The disclosure for this sale can be found here. Insiders have sold 39,135 shares of company stock valued at $929,740 in the last ninety days.
TCDA stock traded up $0.13 on Friday, hitting $24.87. 34,671 shares of the company were exchanged, compared to its average volume of 161,212. Tricida Inc has a twelve month low of $19.43 and a twelve month high of $40.10. The company has a quick ratio of 12.68, a current ratio of 12.68 and a debt-to-equity ratio of 0.11.
Separately, Zacks Investment Research raised shares of Tricida from a “hold” rating to a “buy” rating and set a $26.00 price objective for the company in a research report on Thursday, January 10th.
Tricida, Inc operates as a pharmaceutical company. It focuses on the development and commercialization of TRC101, a non-absorbed orally-administered polymer drug that has completed Phase III clinical trials to treat metabolic acidosis in patients with chronic kidney disease. The company was founded in 2013 and is headquartered in South San Francisco, California.
See Also: Stock Symbols and CUSIP Explained
Want to see what other hedge funds are holding TCDA? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Tricida Inc (NASDAQ:TCDA).
Receive News & Ratings for Tricida Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tricida and related companies with MarketBeat.com's FREE daily email newsletter.